It was demonstrated that, in a mouse model of obesity and in a palmitic acid (PA)-treated cardiomyocyte cell line, ghrelin treatment and/or overexpression activated the complementary H19/miR-29a/IGF-1 pathway, contributing to its cardioprotective action [183]. The gene discussed is GHRL; the disease is obesity disorder.